肿瘤(癌症)患者之家
首页
癌症知识
肿瘤中医药治疗
肿瘤药膳
肿瘤治疗技术
前沿资讯
登录/注册
VIP特权

文章目录

大颗粒淋巴细胞白血病中影响STAT通路和T细胞活化的新体细胞突变

Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation

原文发布日期:2013-12-06

DOI: 10.1038/bcj.2013.65

类型: Original Article

开放获取: 是

英文摘要:

摘要翻译: 

原文链接:

文章:

大颗粒淋巴细胞白血病中影响STAT通路和T细胞活化的新体细胞突变

Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation

原文发布日期:2013-12-06

DOI: 10.1038/bcj.2013.65

类型: Original Article

开放获取: 是

 

英文摘要:

T-cell large granular lymphocytic (T-LGL) leukemia is a clonal disease characterized by the expansion of mature CD3+CD8+ cytotoxic T cells. It is often associated with autoimmune disorders and immune-mediated cytopenias. Our recent findings suggest that up to 40% of T-LGL patients harbor mutations in the STAT3 gene, whereas STAT5 mutations are present in 2% of patients. In order to identify putative disease-causing genetic alterations in the remaining T-LGL patients, we performed exome sequencing from three STAT mutation-negative patients and validated the findings in 113 large granular lymphocytic (LGL) leukemia patients. On average, 11 CD8+ LGL leukemia cell-specific high-confidence nonsynonymous somatic mutations were discovered in each patient. Interestingly, all patients had at least one mutation that affects either directly the STAT3-pathway (such as PTPRT) or T-cell activation (BCL11B, SLIT2 and NRP1). In all three patients, the STAT3 pathway was activated when studied by RNA expression or pSTAT3 analysis. Screening of the remaining 113 LGL leukemia patients did not reveal additional patients with same mutations. These novel mutations are potentially biologically relevant and represent rare genetic triggers for T-LGL leukemia, and are associated with similar disease phenotype as observed in patients with mutations in the STAT3 gene.

 

摘要翻译: 

T细胞大颗粒淋巴细胞(T-LGL)白血病是一种以成熟CD3+CD8+细胞毒性T细胞扩增为特征的克隆性疾病,常与自身免疫性疾病和免疫介导的血细胞减少相关。我们近期研究发现,高达40%的T-LGL白血病患者携带STAT3基因突变,而STAT5基因突变仅见于2%的患者。为在其余未发现STAT基因突变的T-LGL白血病患者中鉴定潜在致病性遗传变异,我们对三例STAT突变阴性患者进行外显子组测序,并在113例大颗粒淋巴细胞(LGL)白血病患者中验证了相关发现。平均每位患者体内发现11个CD8+ LGL白血病细胞特异性的高可信度非同义体细胞突变。值得注意的是,所有患者均携带至少一个直接影响STAT3通路(如PTPRT)或T细胞活化(BCL11B、SLIT2和NRP1)的突变。通过RNA表达或pSTAT3分析证实,这三例患者的STAT3通路均被激活。在其余113例LGL白血病患者的筛查中,未发现相同突变的病例。这些新型突变可能具有生物学相关性,代表了T-LGL白血病的罕见遗传触发因素,并与STAT3基因突变患者中观察到的疾病表型相似。

 

原文链接:

Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation

相关文章

文章:肿瘤抗原优先来源于黑色素瘤和非小细胞肺癌中未突变的基因组序列
文章:年龄相关的烟酰胺腺嘌呤二核苷酸下降驱动CAR-T细胞衰竭
文章:MCSP+转移创始细胞在人类黑色素瘤转移定植早期激活免疫抑制
文章:脂质纳米颗粒递送合成抗原使实体瘤对car介导的细胞毒性敏感
文章:食管癌新辅助治疗中的进化和免疫微环境动力学
文章:CHD1缺失重编程srebp2驱动的胆固醇合成,在spop突变的前列腺肿瘤中促进雄激素响应性生长和去势抵抗
文章:对TIL细胞治疗无反应的转移性非小细胞肺癌患者的T细胞和新抗原保留受损的时间序列分析
文章:策展的癌细胞图谱提供了单细胞分辨率的肿瘤的全面表征
文章:以人群为基础的胶质瘤分子景观分析在青少年和年轻人揭示胶质瘤形成的见解
文章:肿瘤细胞上的PILRα与T细胞表面蛋白CD99相互作用抑制抗肿瘤免疫

……